Nanyang Biologics and Precisya Global Inc Partner to Accelerate AI-Driven Validation of Natural Compounds for Genetic Diseases

Nanyang Biologics (NYB) and Precisya Global Inc (PGI) have announced a strategic collaboration aimed at validating the therapeutic benefits of natural compounds against genetic markers associated with chronic diseases. The partnership, which leverages PGI's genomic big data analytics and NYB's extensive natural compound libraries and AI capabilities, seeks to accelerate the development of nature-based treatments with enhanced precision and efficiency. At the core of this collaboration is NYB's proprietary Drug-Target Interaction Graph Neural Network (DTIGN), an AI model that has shown a 27.03% improvement in prediction accuracy compared to other leading methods. DTIGN greatly enhances the identification of active compounds, thereby speeding up the early stages of drug discovery. NYB is committed to building one of the world's largest natural compound libraries, and the integration of DTIGN into the screening process holds the potential to uncover new therapeutic opportunities rapidly and accurately. Precisya Global Inc will contribute its advanced genomic data analysis platforms and deep genetic expertise, drawing from over 22 million scientific publications. PGI will provide secure access to anonymized patient genomic data, adhering to strict privacy regulations, and offer bioinformatic analysis to pinpoint disease-relevant biomarkers. By combining these resources with NYB's natural compounds, the partnership aims to identify and validate correlations between compound responses and genetic variants. The initiative bridges the gap between genomic analysis and natural compound research, with the goal of developing personalized, nature-based treatments for genetic diseases. These treatments promise better health outcomes, reduced side effects, and more cost-effective solutions. Roland Ong, Founder and Chairman of Nanyang Biologics, emphasized the significance of this collaboration: "This partnership represents a substantial leap forward in precision medicine. By merging our natural compound expertise and DTIGN technology with PGI's genomic capabilities, we can create more targeted and effective treatments while significantly lowering the time and costs traditionally associated with drug discovery." Comprehensive validation will be conducted through in vitro and in vivo assays, utilizing joint biobanks and patient samples. This integrated approach ensures that potential therapeutic compounds are rigorously tested and validated, maintaining high scientific standards throughout the process. About Precisya Global Inc Precisya Global Inc (PGI) is a pioneering deep health technology company that specializes in genomic big data and unique algorithms. PGI's technology maps the genetic interference patterns across entire metabolic pathways, identifying both causative and associative factors of chronic disease expression. With its state-of-the-art technology platform and extensive genomic database, PGI provides precise, data-driven insights that facilitate personalized healthcare solutions and expedite the development of plant-based therapeutic compounds. About Nanyang Biologics Nanyang Biologics (NYB) is a biotechnology company that uses AI and biological data to study drug-target interactions in disease pathways. By leveraging its AI platform and vast compound libraries, NYB identifies promising therapeutic molecules and optimizes them for maximum effectiveness. The company's advanced machine learning techniques are instrumental in driving the discovery of next-generation treatments for cancer and chronic diseases, making the development process faster and more efficient.